Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (NCT05063552)
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
🩺 Plain-English Summary (8th-Grade Level)
This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.
Who can join: Review the eligibility criteria below.
Location: University of Arkansas for Medical Sciences — Little Rock, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (172 Sites)
Showing the first 25 of 172 sites.
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Epic Care-Dublin — Dublin, California
- Epic Care Partners in Cancer Care — Emeryville, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Contra Costa Regional Medical Center — Martinez, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- VA Palo Alto Health Care System — Palo Alto, California
- Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
- Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
- Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
- Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
- Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
- Smilow Cancer Hospital Care Center at Saint Francis — Hartford, Connecticut
- Yale University — New Haven, Connecticut
- Yale-New Haven Hospital North Haven Medical Center — North Haven, Connecticut
- Smilow Cancer Hospital-Orange Care Center — Orange, Connecticut
- Smilow Cancer Hospital Care Center at Long Ridge — Stamford, Connecticut
- Smilow Cancer Hospital-Torrington Care Center — Torrington, Connecticut
- Smilow Cancer Hospital Care Center-Trumbull — Trumbull, Connecticut
- Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut
- Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck — Tampa, Florida
- Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — Columbus, Ohio
- TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer — Atlanta, Georgia
- Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial — Atlanta, Georgia
- Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — Atlanta, Georgia
Explore by condition: All Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.